DEF: LENSAR Sets 2025 Annual Meeting, Board Elections

Sentiment:

Proxy Statement 5 November 2025 7:00 AM

LENSAR, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 18, 2025, to elect Class II directors and ratify its independent accounting firm.

Capital raiseOn May 12, 2023, the company entered into a Securities Purchase Agreement with NR-GRI Partners, LP (an affiliate of North Run) for a private placement of 20,000 shares of Series A Convertible Preferred Stock and Warrants to purchase 4,367,246 shares of common stock for an aggregate gross purchase price of $20.0 million.The Preferred Shares and Warrants were issued on May 18, 2023.As part of the agreement, the company reimbursed North Run for transaction expenses of approximately $241,000.

Summary

The 2025 Annual Meeting of Stockholders will be held virtually on Thursday, December 18, 2025, at 11:00 a.m. Eastern Time.
Stockholders of record as of October 24, 2025, are entitled to vote at the Annual Meeting.
Proposals include the election of Nicholas T. Curtis, Todd B. Hammer, and Aimee S. Weisner as Class II directors for terms expiring in 2028.
Stockholders will also vote to ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025.
The Annual Meeting will only occur if the contemplated merger with Alcon Research, LLC is not completed by the meeting date.
Executive compensation for 2024 totaled $1,576,634 for CEO Nicholas T. Curtis, $1,023,141 for COO Alan B. Connaughton, and $809,734 for CFO Thomas R. Staab, II.
Annual bonuses for 2024 were paid based on corporate objectives achieved at 128% of targeted levels.
North Run Capital, LP and its affiliates beneficially own 55.4% of the company's outstanding common stock and 100% of its Series A Convertible Preferred Stock, representing 45.5% of combined voting power.

Sentiment

Score: 6

Explanation: The filing is a routine proxy statement for an annual meeting, indicating standard corporate governance practices. Positives include strong bonus achievement for executives and robust board oversight. The primary uncertainty is the mention of a 'contemplated merger with Alcon Research, LLC,' which could significantly alter the company's future, but the filing itself doesn't provide details to assess its sentiment.

Positives

The Board of Directors unanimously recommends the re-election of experienced directors and the ratification of the independent accounting firm.
The Audit Committee consists of financially literate and independent members, with all four qualifying as audit committee financial experts.
The Compensation Committee engaged an independent outside compensation consultant (Pay Governance LLC) and determined there were no conflicts of interest.
Annual bonuses for 2024 were paid based on corporate objectives achieved at 128% of targeted levels, indicating strong performance against internal goals.
The company has adopted a clawback policy in accordance with Nasdaq rules, promoting responsible management and accountability.

Negatives

The occurrence of the Annual Meeting is contingent on the non-completion of a contemplated merger with Alcon Research, LLC, introducing significant uncertainty about the company's future as an independent entity.

Risks

Uncertainty surrounding the contemplated merger with Alcon Research, LLC, as the Annual Meeting's occurrence is contingent on its non-completion.
Financial risks, cybersecurity, information and data protection risks are overseen by the audit committee.
Risks relating to the company's executive compensation plans and arrangements, and human capital management are overseen by the compensation committee.
Risks associated with the company's corporate governance framework and environmental and social matters are overseen by the nominating and corporate governance committee.

Future Outlook

The company's future as an independent entity is contingent on the non-completion of a contemplated merger with Alcon Research, LLC. If the merger does not occur, the company will proceed with its annual meeting to elect directors and ratify its accounting firm. Performance Stock Units (PSUs) granted to executives are tied to future cumulative one-year trailing revenues reaching $75 million by December 31, 2026, and $100 million by December 31, 2027, indicating specific revenue growth targets.

Management Comments

On behalf of the Board of Directors and management, it is my pleasure to express our appreciation for your continued support. (William J. Link, PhD, Chairman of the Board)
Your vote is important to us. Please act as soon as possible to vote your shares. (William J. Link, PhD, Chairman of the Board)
We want to provide expanded access, improved communication and cost savings for our stockholders and the Company while providing stockholders the same rights and opportunities to participate as they would have at an in-person meeting. (Regarding virtual meeting)
We believe that hosting a virtual meeting is in the best interest of the Company and its stockholders and a virtual meeting enables increased stockholder attendance and participation because stockholders can participate from any location around the world. (Regarding virtual meeting)

Industry Context

This filing is a standard proxy statement, primarily focused on corporate governance and executive compensation. It does not provide specific industry analysis or comparisons to competitors beyond the biographical information of directors who have served on boards of other ophthalmic or medical device companies. The mention of a 'contemplated merger with Alcon Research, LLC' suggests potential consolidation or strategic shifts within the ophthalmic medical device sector.

Comparison to Industry Standards

The company's board includes directors with extensive experience in the ophthalmology and medical device industries, including former executives and board members of companies like Glaukos Corporation, STAAR Surgical Company, Edwards Lifesciences Corporation, and Allergan, Inc., which aligns with industry best practices for specialized sectors.
The use of an independent compensation consultant (Pay Governance LLC) for executive compensation review is a common practice among publicly traded companies to ensure competitive and fair compensation structures.
The adoption of a clawback policy aligns with current corporate governance trends and Nasdaq rules, demonstrating adherence to modern accountability standards.
The virtual annual meeting format is increasingly common, offering expanded access and cost savings, aligning with evolving shareholder engagement practices.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Class II Director	Nicholas T. Curtis (current)	Nicholas T. Curtis (nominated for re-election)	2028 Annual Meeting (if elected)	Nominated for re-election to a new three-year term.
Class II Director	Todd B. Hammer (current)	Todd B. Hammer (nominated for re-election)	2028 Annual Meeting (if elected)	Nominated for re-election to a new three-year term.
Class II Director	Aimee S. Weisner (current)	Aimee S. Weisner (nominated for re-election)	2028 Annual Meeting (if elected)	Nominated for re-election to a new three-year term.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	Board size fixed at eight directors, divided into three classes (Class I, II, III), with terms staggered over three years.	Ongoing	Ensures continuity and staggered director elections.
Board Leadership	The roles of Chairman of the Board (William J. Link, PhD, independent) and Chief Executive Officer (Nicholas T. Curtis) are separate.	Ongoing	Provides an appropriate balance between strategic direction and operational oversight, with independent board leadership.
Director Independence	Seven of eight directors (Mr. Ellis, Mr. Hammer, Dr. Lindstrom, Dr. Link, Ms. OFarrell, Ms. Weisner, Mr. Winer) are determined to be independent under Nasdaq rules.	Ongoing	Ensures a strong independent voice on the Board and its committees, enhancing oversight and accountability.
Committee Composition	Audit Committee: Elizabeth G. OFarrell (Chair), William J. Link, PhD, Richard L. Lindstrom, MD, Gary M. Winer. All are financially literate, independent, and qualify as audit committee financial experts.	Ongoing	Provides robust oversight of financial reporting, internal controls, and risk management.
Committee Composition	Compensation Committee: Richard L. Lindstrom, MD (Chair), William J. Link, PhD, Todd B. Hammer, Aimee S. Weisner, Gary M. Winer. All are independent.	Ongoing	Ensures independent review and recommendations for executive and director compensation, aligning with shareholder interests.
Committee Composition	Nominating and Corporate Governance Committee: Gary M. Winer (Chair), Thomas B. Ellis, William J. Link, PhD, Richard L. Lindstrom, MD. All are independent.	Ongoing	Oversees board composition, director nominations, corporate governance guidelines, and environmental/social matters.
Policy Adoption	Adopted Corporate Governance Guidelines, Code of Business Conduct and Ethics, and Insider Trading Compliance Policy (including anti-hedging policy).	Ongoing	Establishes clear standards for ethical conduct, board operations, and compliance with securities laws.
Policy Adoption	Instituted a clawback policy in accordance with Nasdaq's final rules implementing incentive-based compensation recovery provisions.	October 2, 2023	Enhances accountability for executive officers and discourages conduct detrimental to company growth by requiring forfeiture of erroneously awarded incentive compensation.

Related Party Transactions

On May 12, 2023, the company entered into a Securities Purchase Agreement with NR-GRI Partners, LP (an affiliate of North Run) for a private placement of 20,000 shares of Series A Convertible Preferred Stock and Warrants to purchase 4,367,246 shares of common stock for an aggregate gross purchase price of $20.0 million.
As of October 24, 2025, Mr. Ellis, Mr. Hammer, and North Run beneficially owned 55% of the company's outstanding common stock.
The company agreed to increase the Board size from seven to nine directors following the 2023 Annual Meeting and appointed two North Run designees (Thomas B. Ellis and Todd B. Hammer) to the Board, providing North Run with continuing director designation rights.
The company reimbursed North Run for its transaction expenses in an amount of approximately $241,000.
The company has entered into indemnification agreements with each of its directors and executive officers, which may be broader than specific indemnification provisions under Delaware law.

Stakeholder Impact

Shareholders will vote on key governance matters, including director elections and auditor ratification, and should monitor the status of the contemplated merger with Alcon Research, LLC.
Executive officers' compensation is detailed, and their employment agreements include provisions for severance and accelerated equity vesting under certain termination or change-in-control scenarios.
Employees benefit from a 401(k) plan with matching contributions and other standard health and welfare benefits.
PricewaterhouseCoopers LLP's role as the independent registered public accounting firm for 2025 is subject to shareholder ratification, ensuring continued financial oversight.

Next Steps

Stockholders are encouraged to vote on director nominees and the ratification of the independent accounting firm by December 17, 2025 (online/phone) or during the virtual meeting on December 18, 2025.
The Annual Meeting will be held on December 18, 2025, if the merger with Alcon Research, LLC is not completed.
Stockholders can submit proposals for the 2026 Annual Meeting by July 8, 2026 (pursuant to Rule 14a-8) or provide notice between August 20, 2026, and September 19, 2026 (pursuant to Bylaws).

Key Dates

Date	Description
May 12, 2023	Company entered into a Securities Purchase Agreement with NR-GRI Partners, LP for a private placement.
May 18, 2023	Preferred Shares and Warrants were issued to NR-GRI Partners, LP.
May 25, 2023	Thomas B. Ellis and Todd B. Hammer were appointed to the Board of Directors.
August 1, 2023	Stockholders approved the issuance of common stock upon conversion of Series A Convertible Preferred Stock and exercise of Warrants to NR-GRI Partners, LP.
January 22, 2024	Effective date for increases in executive base salaries.
May 6, 2024	RSUs and PSUs granted to named executive officers under the 2020 Plan.
December 31, 2024	Fiscal year-end for financial statements and equity compensation plan information.
February 2025	Board of Directors approved cash bonus payments for the 2024 fiscal year.
May 23, 2025	Non-employee directors received annual RSU awards.
October 24, 2025	Record Date for stockholders entitled to notice of and to vote at the Annual Meeting.
November 5, 2025	Notice of Annual Meeting and Proxy Statement first distributed or made available.
December 17, 2025	Deadline for Internet and Telephone voting (11:59 p.m. Eastern Time).
December 18, 2025	2025 Annual Meeting of Stockholders (11:00 a.m. Eastern Time).
December 31, 2026	Deadline for 50% PSU vesting if cumulative one-year trailing revenues equal or exceed $75 million.
December 31, 2027	Deadline for remaining 50% PSU vesting if cumulative one-year trailing revenues equal or exceed $100 million.
July 8, 2026	Deadline for stockholder proposals for the 2026 Annual Meeting (pursuant to Rule 14a-8).
August 20, 2026	Earliest date for stockholder notice of proposals or director nominations for the 2026 Annual Meeting (pursuant to Bylaws).
September 19, 2026	Latest date for stockholder notice of proposals or director nominations for the 2026 Annual Meeting (pursuant to Bylaws).

Recommendation

hold

This filing is a routine proxy statement for an annual meeting, primarily focused on corporate governance, director elections, and auditor ratification. It does not contain new material financial performance data or strategic announcements that would warrant a change in investment recommendation. While the mention of a 'contemplated merger' introduces a significant future contingency, without further details on its status or likelihood, it does not provide a basis for a 'buy' or 'sell' recommendation based solely on this document. Investors should hold and monitor for updates on the merger.

Keywords

LENSAR, proxy statement, annual meeting, corporate governance, director election, independent auditor, executive compensation, stock ownership, related party transactions, Alcon merger, ophthalmology, medical device

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.